Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmani donovani infected BALB/c mice

K. C. Carter, T. F. Dolan, J. Alexander , A.J. Baillie, C McColgan

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The efficacy of various sodium stibogluconate formulations against Leishmania donovani has been investigated using a BALB/c mouse model of visceral leishmaniasis. Only one therapy, multiple dosing with drug loaded sonicated vesicles, liposomes or niosomes, was found to be effective against parasites in the liver, spleen and bone marrow. Other treatments significantly reduced parasite liver burdens but either failed to effect spleen and bone marrow parasites, or were effective but toxic. Prophylactic treatment with sodium stibogluconate preparations, six days before infection, reduced parasite multiplication in the liver (free, niosomal and liposomal drug) and the spleen (sonicated, drug loaded niosomes only), but had no suppressive effect on bone marrow parasite burdens compared with controls. These results indicate that in-vivo sodium stibogluconate persists in some compartments at parasiticidal concentrations and that failure to reach this concentration at some sites of infection such as bone marrow, is the cause of treatment failure and relapse.
LanguageEnglish
Pages87-91
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume41
Issue number2
DOIs
Publication statusPublished - 1 Feb 1989

Fingerprint

Drug Carriers
Visceral Leishmaniasis
Antimony Sodium Gluconate
Parasites
Spleen
Bone Marrow
Liposomes
Liver
Pharmaceutical Preparations
Leishmania donovani
Parasitic Diseases
Poisons
Treatment Failure
Therapeutics
Recurrence
Infection

Keywords

  • visceral leishmaniasis
  • parasites
  • mice
  • Leishmania donovani
  • sodium stibogluconate

Cite this

@article{35012d3edfeb409b953ca94492836643,
title = "Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmani donovani infected BALB/c mice",
abstract = "The efficacy of various sodium stibogluconate formulations against Leishmania donovani has been investigated using a BALB/c mouse model of visceral leishmaniasis. Only one therapy, multiple dosing with drug loaded sonicated vesicles, liposomes or niosomes, was found to be effective against parasites in the liver, spleen and bone marrow. Other treatments significantly reduced parasite liver burdens but either failed to effect spleen and bone marrow parasites, or were effective but toxic. Prophylactic treatment with sodium stibogluconate preparations, six days before infection, reduced parasite multiplication in the liver (free, niosomal and liposomal drug) and the spleen (sonicated, drug loaded niosomes only), but had no suppressive effect on bone marrow parasite burdens compared with controls. These results indicate that in-vivo sodium stibogluconate persists in some compartments at parasiticidal concentrations and that failure to reach this concentration at some sites of infection such as bone marrow, is the cause of treatment failure and relapse.",
keywords = "visceral leishmaniasis, parasites, mice, Leishmania donovani, sodium stibogluconate",
author = "Carter, {K. C.} and Dolan, {T. F.} and J. Alexander and A.J. Baillie and C McColgan",
year = "1989",
month = "2",
day = "1",
doi = "10.1111/j.2042-7158.1989.tb06399.x",
language = "English",
volume = "41",
pages = "87--91",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
number = "2",

}

Visceral leishmaniasis : drug carrier characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmani donovani infected BALB/c mice. / Carter, K. C.; Dolan, T. F. ; Alexander , J.; Baillie, A.J.; McColgan, C.

In: Journal of Pharmacy and Pharmacology, Vol. 41, No. 2, 01.02.1989, p. 87-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Visceral leishmaniasis

T2 - Journal of Pharmacy and Pharmacology

AU - Carter, K. C.

AU - Dolan, T. F.

AU - Alexander , J.

AU - Baillie, A.J.

AU - McColgan, C

PY - 1989/2/1

Y1 - 1989/2/1

N2 - The efficacy of various sodium stibogluconate formulations against Leishmania donovani has been investigated using a BALB/c mouse model of visceral leishmaniasis. Only one therapy, multiple dosing with drug loaded sonicated vesicles, liposomes or niosomes, was found to be effective against parasites in the liver, spleen and bone marrow. Other treatments significantly reduced parasite liver burdens but either failed to effect spleen and bone marrow parasites, or were effective but toxic. Prophylactic treatment with sodium stibogluconate preparations, six days before infection, reduced parasite multiplication in the liver (free, niosomal and liposomal drug) and the spleen (sonicated, drug loaded niosomes only), but had no suppressive effect on bone marrow parasite burdens compared with controls. These results indicate that in-vivo sodium stibogluconate persists in some compartments at parasiticidal concentrations and that failure to reach this concentration at some sites of infection such as bone marrow, is the cause of treatment failure and relapse.

AB - The efficacy of various sodium stibogluconate formulations against Leishmania donovani has been investigated using a BALB/c mouse model of visceral leishmaniasis. Only one therapy, multiple dosing with drug loaded sonicated vesicles, liposomes or niosomes, was found to be effective against parasites in the liver, spleen and bone marrow. Other treatments significantly reduced parasite liver burdens but either failed to effect spleen and bone marrow parasites, or were effective but toxic. Prophylactic treatment with sodium stibogluconate preparations, six days before infection, reduced parasite multiplication in the liver (free, niosomal and liposomal drug) and the spleen (sonicated, drug loaded niosomes only), but had no suppressive effect on bone marrow parasite burdens compared with controls. These results indicate that in-vivo sodium stibogluconate persists in some compartments at parasiticidal concentrations and that failure to reach this concentration at some sites of infection such as bone marrow, is the cause of treatment failure and relapse.

KW - visceral leishmaniasis

KW - parasites

KW - mice

KW - Leishmania donovani

KW - sodium stibogluconate

U2 - 10.1111/j.2042-7158.1989.tb06399.x

DO - 10.1111/j.2042-7158.1989.tb06399.x

M3 - Article

VL - 41

SP - 87

EP - 91

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 2

ER -